MEDICAL PRODUCTS
Human Ultracell V IM
Human Ultracell V Oral
Human Citoplacell 3G
Revercell 3G
Cellorgane Multi-Complex 3G
Androcell 3G
Biofemin 3G
Bioenzym 3G
Celltox 3G
Mekenz H7 3G
Cellorgane Man
Cellorgane Woman
Formula 1 Skin & Muscle
Formula 2 Liver
Formula 3 Heart-Artery-Vein
Formula 4 Bone-Cartilage
Formula 5 Kidney - Nephrons
Formula 6 Lungs
Formula 7 Brain-Hypothalamus-Pituitary
Formula 8 Adrenal Gland
Formula 9 Thymus - Spleen
Formula 10 Pancreas
Formula 11 Esophagus-Stomach-Intestines
LOGGED IN
No one logged in.

TRAINING FOR DOCTORS – INTRODUCTION

The human cell, the smallest functional unit in the human body, is responsible for producing all the elements and biological processes necessary for life, from conception and development to maintenance of the body. The progressive decrease of a cell's functions is consequently reflected in the progressive deterioration and death of the body.

Modern medicine has made unprecedented strides in the treatment of trauma, burns and bacterial infections. In the case of viral infections, however, with the exception of some preventative vaccines for past viral scourges such as smallpox, chicken pox, polio, etc., treatment options are still very limited and we rely on the strength of the immune system for healing.

Modern medicine cannot do much, either, in the face of degenerative diseases such as Alzheimer’s, Parkinson's, etc, even less against autoimmune diseases such as Rheumatoid Arthritis, Lupus and Multiple Sclerosis, and almost nothing against genetic diseases.

Unquestionably, there is a relationship between ageing and disease, particularly when it comes to degenerative and autoimmune diseases and catastrophic diseases such as cancer. This is mainly due to the fact that our immune systems weaken with age and can eventually start to react against the body's own tissues.

Ageing occurs at the cellular level, as cell functions are progressively impaired over time by the cumulative effects of, among other things, the oxidation of free radicals, environmental and industrial toxins, pesticides, bad eating habits and inactivity.

In short, all diseases viral, bacterial, degenerative, autoimmune and genetic originate and develop in our cells, just as ageing does. Therefore, treatments should focus on normalisation and healing at the cellular and microbiological level.

CELLULAR RENOVATION THERAPIES

Since the 1930s, Biocell’s laboratories in Switzerland and France have devoted many years to research into improving health and slowing the ageing process, through innovative approaches that focus on supplying specific cellular nutrients such as enzymes, proteins and essential amino acids, reinforced with natural phytochemicals and antioxidant vitamins. This research builds on the work of Dr. Paul Niehans, who gained worldwide fame by providing cellular therapies based on glands and tissue extracts from sheep.

These expensive treatments have benefited dignitaries, politicians and celebrities, including: Pope Pius XII, the British Royal Family, Emperor Hirohito of Japan, Winston Churchill, Konrad Adenauer, Charles de Gaulle, Greta Garbo, Charlie Chaplin, and many more.

Time and research have thrown new light onto the functioning of different areas of the body such as the immune system, the human genome and molecular level cell function. Building on these developments, Biocell’s laboratories have been perfecting their cellular therapies, in order to create Cellular Renovation Therapy, which focus on more effectively restoring and renewing cell functions, thus preventing degenerative and functional damage to the body from occurring.

CAUSES OF CELL DETERIORATION

Over time, cellular functions deteriorate, primarily due to oxidative stress on the cell's tissues caused by repeated exposure to free radicals. Another process that contributes to cell deterioration is glycation, the formation of products from a non-enzymatic reaction between proteins and reducing sugars. This process hinders the mobility of cellular membranes and particularly affects long-lived proteins such as collagen.

FREE RADICALS are highly reactive oxygen molecules that are missing an electron, and are produced during the synthesis of ATP in mitochondria. These molecules react rapidly with any other molecule that is in proximity, damaging vital proteins and enzymes and weakening cellular structures. Proteins damaged by free radicals affect the cell's metabolism by interfering with the production or effect of other proteins or molecules.

The greater the exposure to pollutants, fatty foods, sunlight, cigarette smoke, alcohol, stress, etc, the greater the production of free radicals.

Cells have access to both natural antioxidants such as superoxide dismutase, and antioxidants from plant-based foods, which neutralise free radicals by donating the electrons missing in free radicals in order to transform them back into stable oxygen molecules. However, these natural antioxidants are not enough to neutralise all free radicals.

The higher the production of unneutralised free radicals in the body, the greater the rate of cellular, organic and visible ageing within a person. In this way, each individual experiences ageing differently, depending on his or her lifestyle.

GLYCATION

Glycation is a non-enzymatic reaction between a reducing sugar, such as glucose, and a protein. After some weeks, this reaction gives rise to a heterogeneous group of stable, irreversible, viscous products that mainly accumulate in long-living tissues that are exposed to high levels of glucose, such as haemoglobin in the intracellular spaces of erythrocytes, or collagen, the predominant protein in the extracellular matrix of connective tissues such as skin, tendons and bones. These advanced glycation end products (AGEs) can contribute to hardening and loss of flexibility in collagen-rich tissues such as the aorta, the dura mater or the skin. They can also contribute to atherosclerosis, kidney disease, cataracts, clouding of the transparent cornea and peripheral vascular disorders.

The collagen modified by AGEs can form cross links with serum proteins such as low-density lipoproteins, albumin or immunoglobulin, contributing to atherosclerosis, the thickening of the basement membrane in renal tissues and occlusion of peripheral vessels.

Recent studies have found that accumulations of beta-amyloid plaques in the brain, a fundamental characteristic of Alzheimer's disease, contain almost three times as many AGEs as similar age-matched control samples. They have also found that amino groups in nucleic acids can react with glucose, producing modified compounds like those described above, which could lead to mutagenic effects.

Since AGE generation is directly linked with blood glucose levels, glycation explains why diabetic individuals suffer from increased risks of cataracts, nephropathy, peripheral circulation problems and an increased ageing rate.

CELLULAR EFFICIENCY

The repeated, unneutralised action of free radicals and glycation affects proteins, enzymes and tissues and eventually exceeds a cell's ability to repair and clean itself, resulting in an accumulation of unwanted biomaterial both inside and outside the cell, affecting its efficiency.

This loss of efficiency is manifested in lower protein and lipid production, particularly essential enzymes, hormones, collagen, insulin, etc, and in the cell's decreased ability to generate energy (ATP) via reduction of the NAD (nicotinamide adenine dinucleotide) coenzyme involved in the electron transport chain, thus generating clear ageing symptoms.

Furthermore, this loss of cellular efficiency can result in DNA transcription errors both when producing internal proteins, or when preparing for mitosis. In the case of the former, unnecessary and undesirable proteins may be produced that can compromise cellular function even further, and in the latter case mutations may occur during mitosis during the S interphase and then go uncorrected in the Gap 2 interphase, with failures in the apoptosis mechanism.

WHAT CAN WE DO?

To reset cellular efficiency and the deterioration caused by ageing, we can do two things, one being highly draconian and practically impossible to carry out. This is the practice of calorie restriction, which has produced astonishing results in animals in captivity since the 1930s. The other option is Biocell Cellular Renovation Therapy, which induces the effects of calorie restriction without having to endure extreme hunger every day.

CALORIE RESTRICTION

In 1934, Cornell University announced that in a study conducted by Clive McCay and Mary Crowell, rats submitted to a calorie-restricted diet with high nutritional value, eating 40% less than control rats, were able to stay healthier and live nearly twice as long as the control rats. These results have been confirmed in several research centres around the world and have been extended to a number of larger animals, with similar results. Human trials have also shown improvements in the markers associated with age: systolic pressure, blood glucose, insulin resistance, cholesterol, etc. However similar improvements have also been observed in individuals who have not gone on a calorie-restricted diet, but who have still improved their eating and physical habits.

The main problem with a calorie restricted diet in humans is that it subjects the individual to a state of near starvation which, in addition to producing a horrible hunger, decreases their physical and mental faculties.

BIOCELL CELLULAR RENOVATION THERAPIES

Given the connection established between nutrients and the ageing rate thanks to experiments with caloric restriction, the major laboratories around the world involved in research into ageing have, over the last few decades and especially in the last 10 years, concentrated their efforts on developing products that emulate the physiological results of a calorie-restricted diet.

Biocell Laboratories have been very successful in this regard, and have developed a series of Cellular Renovation Therapy therapies which, to a greater or lesser degree, depending on the patient's needs, manage to induce the beneficial effects of calorie restriction without requiring any of the inherent hardships.

MODE OF ACTION

Most experts agree that the benefits of calorie restriction derive from the lower production of free radicals, from the processing of fewer calories and from the activation of survival genes known as SIRT1 and SIRT2, or Sirtuins. Sirtuins are responsible for silencing genes which have wrongly become active, due to faulty selection controls in DNA segments during transcription of the instructions for protein and lipid generation.

Biocell Cellular Renovation Therapies have the same effect as lower free radical production, by using a high antioxidant enzyme content maximised by peptide catalysts to neutralise many of these free radicals. They also acheive expression of survival genes through catalysing nutrients such as resveratrol and other activators.

Thirdly, Biocell Therapies, with their embryonic tissues and natural enzymes, are able to reactivate the cell's self-cleaning and organic waste recycling processes, or ‘Autophagy,’ which occurs in the cell's lysosomes, or digestive bags.

The embryonic tissues and natural enzymes in Biocell therapies also help to increase the amount of NAD coenzymes, which are vital for restoring cells’ metabolic efficiency (See ATP synthesis).

These four effects result in an effective cell renewal, returning cells to their normal function.

In short, it can be stated that Biocell Cellular Renovation Therapies incorporate the best of conventional cell therapies embryonic tissues combined with catalysing nutrients such as amino acids, enzymes, peptides and natural antioxidants and combine these with the optimal stimulation of the expression of survival genes (Sirtuins) and stimulation of self-cleaning and organic waste recycling processes, thereby achieving efficient cell renewal, without the need to expose users to the extreme rigors of a calorie restricted diet.

As both ageing and degenerative and autoimmune diseases all begin to develop in cells long before symptoms appear, Biocell therapies are firstly aimed at prevention, and then at aiding conventional healing processes.

PHARMACODYNAMICS

The components of the various formulas are delivered to the cells, either directly through the bloodstream or indirectly in the case of oral products, and are incorporated into the cells via one of several cellular transport methods, depending on the size of the molecules of the elements in question. Large molecules are incorporated into cells by receptor mediated endocytosis, following the series: vesicle, endosome and lysosome. Smaller molecules are incorporated through either simple diffusion or protein-facilitated diffusion, as applicable.

Cell Extracts (solid particles) that have entered the cell via endocytosis are made up of molecules whose atoms are joined together by chemical bonds, which contain energy. Both the matter and energy in these molecules are utilised by the cell, through a process called cell digestion that breaks the molecules down using hydrolase enzymes (pH 4.5) contained in the lysosomes.

The useful parts of the cellular extracts pass into the cytoplasm and are assimilated into it. The parts that are not useful are ejected from the cell.

Assimilated substances have different purposes: the matter can be used to make other molecules, to replace destroyed parts of the cell structure (regeneration), or to release energy.

The incorporation of these various components into the relevant cell tissues is facilitated by the empathy existing between these components and the receptor proteins on the surface of the cell membrane in question.

THE FUNCTIONAL CELL

The main function of cells is to produce and process proteins, lipids and carbohydrates, both for their own use and for the body in general. To do this, they must create their own fuel: adenosine triphosphate (ATP), from the nutrients in the body.

PROTEIN SYNTHESIS

All cells except erythrocytes (red blood cells) have to be able to produce proteins, because proteins are the main "worker" molecules within a cell. Protein production begins in small structures called ribosomes, built in the nucleus of each cell in the form of two separate rRNA (ribosomal ribonucleic acid) molecular units (minor and major) and a variety of proteins, which then combine outside the nucleus when they receive instructions to produce proteins, and then either adhere to the rough endoplasmic reticulum (RER) to produce proteins for the body, or remain floating in the cytoplasm in order to make proteins for the cell itself. The minor ribosomes unit is able to read the transcription of the genetic code for the protein in question and the major unit is able to assemble amino acids to form short chains (peptides) or long chains (proteins) as per the genetic instructions read by the minor unit.

The new protein generated and tagged by the ribosomes passes into the RER or lumen, where carbohydrates are added to it, and it is then folded in keeping with the type of protein it is and its purpose. It is then pushed through the RER, which creates a seal around it, forming a vesicle that transports the protein to the Golgi apparatus. The protein is pushed into the apparatus’ lumen, wherein it is modified with the necessary finishing touches. Eventually, the complete protein exits the apparatus surrounded by a vesicle, from the side of the Golgi apparatus closest to the cell's plasma membrane. The vesicle merges with the membrane so that the protein can be released outside the cell.

Proteins that are manufactured for the cell itself are created in the free ribosomes in the cytoplasm, then follow the same process described above, but do not leave the cell. Everything is executed according to the protein’s earmark tag.

LIPID SYNTHESIS

Lipid synthesis takes place in a cell's smooth endoplasmic reticulum (SER), which is an interconnected network of flattened tubes, sacs and cisternae, joined to the cisternae of the rough reticulum. The SER produces most of the lipids, including cholesterol, needed to develop new cell membranes, with the remainder taking place in the Golgi apparatus. Fatty acids are synthesised in the cytosol and then subsequently inserted in the SER.

Glycolipids are also produced in the SER, and are assembled with support from the Golgi apparatus. Triglycerides are also synthesised, and are stored in the reticulum itself. This process is very active in adipocytes of adipose tissue.

The SER is also primarily responsible for the synthesis of the lipid part of lipoproteins, in the production of steroid hormones and bile acids.

The SER also constitutes the main reservoir of calcium ions needed for muscle contraction, and also actively participates in the detoxification of drugs and metabolites, transforming them into water-soluble compounds that can be excreted in urine.

CARBOHYDRATE SYNTHESIS

Some cells in the body, mostly in the liver and to a lesser extent in the renal cortex, have the ability to synthesise glucose from various carbohydrate sources, such as: glycerol, lactate, propionate and amino acids; i.e, from fatty acids and proteins. This synthesis is called gluconeogenesis and is performed in the cytosol of these cells, before moving to the SER and then finally to the Golgi apparatus in order to be enveloped in a membrane for transport towards the cell’s lipid bilayer, from where it leaves the cell and is absorbed into the bloodstream.

This synthesis process is performed as a last resort when glucose levels in the body drop to critical levels, so that the functions of the brain, central nervous system, the renal medulla and erythrocytes can be maintained.

ADENOSINE TRIPHOSPHATE (ATP) SYNTHESIS

All the cells in the human body except red blood cells, which get their energy through lactic fermentation have to produce their own fuel in order to perform all their processes. This is particularly true for anabolic processes, which build complex molecules. Anabolic processes are endergonic; i.e, they require energy. In contrast, catabolic processes, or the breakdown of complex molecules into more simple ones, generate energy and are therefore called exergonic processes.

The end products resulting from catabolism of the three food groups used by the human body can be used by cells as fuel. These three food groups are Carbohydrates (sugars), Lipids (fats) and Proteins. Carbohydrates are used in the form of monosaccharides, mainly glucose, while lipids are used in the form of fatty acids, and proteins in the form of amino acids. These macromolecules reach the cells via the bloodstream and are easily assimilated and used for ATP synthesis.

Two of the three mentioned macromolecules can be stored in the body. Glucose is stored as glycogen in the liver and muscles, and fatty acids are stored as triglycerides in the cells of the body’s adipose tissue. Amino acids are not stored and are used mainly to synthesise new proteins in cells. The excess is oxidised into urea in order to produce energy.

In the graph below it can be seen how the different macromolecules mentioned result in the production of ATP.

Glucose and fatty acids are oxidised and after several steps, in which some ATP is generated, they are converted into an intermediate fuel in the cellular cytoplasm that is called Acetyl-CoA (AcetylcoenzymeA). This passes into the mitochondria where, through a repeated oxidative process called the Krebs cycle or Citric Acid cycle, ATP is produced and, more importantly, NADH is produced from NAD (nicotinamide adenine dinucleotide), a coenzyme found in the body.

NADH and NAD together, in alternating oxydo-reduction processes, generate an electron transport chain that makes the last step of the ATP production process possible: oxidative phosphorylation. This also occurs in the mitochondria and generates most of the ATP.

The various steps of ATP synthesis are also known as Cellular Respiration, since they require the presence of oxygen for the controlled combustion of cell nutrients and as a result energy is produced in the form of ATP, with CO2 and water as waste products.

The process of ATP generation is further described below, using the example of glucose, the easiest nutrient to use in ATP synthesis.

The first phase of the synthesis process, called glycolysis, involves the oxidation of glucose to create pyruvate, dividing each glucose molecule (of six carbon atoms) into two pyruvate molecules of three carbon atoms each. Then the pyruvate molecules are decarboxylated, producing CO2 and reducing the number of carbon atoms in the pyruvates from 3 to 2. Next, a group of enzymes oxidise the pyruvate by transferring electrons to the NAD transporter, converting it into its reduced form of NADH. In reality, it would actually be NADH + H+ , but for simplification purposes NADH is used.

Other enzymes add the coenzyme A to convert the pyruvate into acetyl-CoA, which along with 2 NADH molecules enters into the Krebs cycle for further processing.

At the beginning of glycolysis, 2 ATP molecules are consumed per molecule of glucose, but at the end of the process 4 molecules of ATP are produced, with a net gain of 2 ATP molecules per molecule of glucose.

The second phase of the process, called the Krebs cycle, consists of a repeating eight-step process of oxidation, reduction and decarboxylation, which results in the creation of two ATP molecules per initial molecule of glucose, the transfer of electrons to 2 molecules of FADH2, another electron carrier, as well as CO2. The Krebs cycle occurs in the mitochondria, and in order to move into the mitochondrial inner membrane, glycolysis must provide the equivalent of 2 ATP.

The third phase of ATP synthesis, called oxidative phosphorylation, also occurs in the mitochondria as a continuation of the Krebs cycle. It is based on the large amount of reduced electron carriers, mainly NADH, that received electrons from the oxidation of intermediate products during glycolysis and the Krebs cycle. These NADH and FADH electrons can now be utilised, with the assistance of ATP synthase, to activate the electron transporting complexes located in the mitochondrial inner membrane, in order to produce ATP based on the existing ADP in the mitochondrial matrix.

Each molecule of NADH is capable of producing 3 ATP molecules through the electron transport chain and each FADH molecule can produce 2 ATP molecules, so that the 8 NADH and the 2 FADH molecules produced in the Krebs cycle per molecule of glucose can generate a total of 28 ATP which, when added to the 2 ATP produced during glycolisis, and the 2 ATP produced in the Krebs cycle, and the 6 ATP coming from the NADH transferred from glycolisis to the electron transport chain, and minus the 2 ATP used to pass into the inner mitochondrial membrane, results in a total of 36 ATP produced during synthesis, per initial molecule of glucose.

As may be observed, the electron carriers NAD/NADH and FAD/FADH in their oxidised and reduced forms are crucial to ATP synthesis, and their decrease due to lower cellular efficiency compromises their metabolic capacity, thus contributing to accelerated ageing.

SUMMARY

Biocell Cellular Renovation Therapies achieve the following positive effects:

Reduced damage by free radicals by neutralising many of these free radicals with high contents of antioxidant enzymes, maximised by catalysing peptides.

Survival gene expression, through activating nutrients such as resveratrol and other gene activators.

Induction of ‘autophagy,’ the process of self cleaning and recycling of unwanted biomaterial accumulated in the cell cytoplasm, through the introduction via the therapies of embryonic tissues and catalytic enzymes.

The embryonic tissues and natural enzymes in Biocell's therapies also help to increase the amount of NAD coenzymes in the cells, vital to restoring cellular metabolic efficiency.

These actions result in effective cell renewal, returning cells to normal function.

Who We Are

Biocell Ultravital™ researches and develops innovative, 100% natural, pharmaceutical-grade bioproducts, on an exclusive basis worldwide. These products optimise cell nutrition and energy, producing a preventative and curative action which, in addition to treating pre-symptoms and symptoms by means of cell renewal, refuels and corrects the cell structure of tissues and organs, preventing the appearance of the functional stress loads which give rise to poor cell formation, degenerative diseases, and their after-effects.

Policies

Product developed under pharmaceutical control according to European CE standards. Made in the EC by Biocell Laboratory France, licensed and authorized by Biocell Ultravital GmbH, Switzerland.

Privacy

This website is governed by applicable laws and government regulations. Please see our Privacy Policy.
Use of this site constitutes your consent to application of such laws and regulations.

© 2017 Biocell Ultravital